TABLE 1.

Overview of clinical approved MET inhibitors for the treatment of NSCLC.

Types of MET inhibitors	Drugs	Chemical structures	Phase	Clinical trial number	Status
Ia	Crizotinib (1)		III	NCT02767804 NCT04632758 NCT03052608 NCT06569420 NCT02838420 NCT02075840	Active
			I/II	NCT01712217 NCT01970865	Completed
			IV	NCT03672643	Recruiting
			II	NCT01945021 NCT02183870 NCT03088930 NCT00932451	Completed
			III	NCT06140836 NCT06082635 NCT04603807	Recruiting
			I/II	NCT05384626	Recruiting
			II	NCT01500824	Withdrawn
			IV	NCT05160922	Active
			I	NCT01579994 NCT01998126	Completed
			I/II	NCT02584634	Terminated
			II	NCT04322578	Recruiting
			III	NCT02737501 NCT01639001 NCT00932893 NCT01828112	Completed
Ib	Capmatinib (2)		II	NCT04460729 NCT05567055 NCT03240393	Withdrawn
			II	NCT02414139 NCT03647488 NCT02750215 NCT01610336 NCT02276027	Completed
			II	NCT04677595	Active
			IV	NCT05110196	Recruiting
			I/II	NCT05488314	Active
			III	NCT04427072	Completed
			III	NCT04816214	Terminated
			I	NCT01911507 NCT01324479	Completed
			II	NCT05642572 NCT03040973	Recruiting
			I	NCT02468661	Terminated
	Savolitinib (3)		III	NCT04923945	Recruiting
			II	NCT02117167	Completed
			II	NCT04322890	Recruiting
			II	NCT03778229 NCT05163249 NCT03833440 NCT04606771 NCT03944772	Active
			III	NCT05261399	Recruiting
			II	NCT04322578	Recruiting
			I	NCT02374645	Completed
			I	NCT02143466	Active
	SAR125844 (4)		I	NCT01391533	Completed
			I	NCT01657214	Completed
			II	NCT02435121	Completed
	Bozitinib (5)		II	NCT03175224	Recruiting
			I/II	NCT04743505 NCT06343064	Recruiting
			I	NCT02896231	Completed
			I/II	NCT03655613	Terminated
	Tepotinib (6)		I/II	NCT04739358	Terminated
			I/II	NCT06083857	Recruiting
			II	NCT02864992 NCT03940703	Active
			I/II	NCT01982955	Completed
	ABN401 (7)		II	NCT05541822	Recruiting
			I	NCT04052971	Recruiting
			I	NCT05248074	Completed
	Elzovantinib (8)		I/II	NCT03993873	Active
	Glumetinib (9)		I/II	NCT04270591	Unknown
II	Cabozantinib (10)		II	NCT02132598	Terminated
			I/II	NCT00596648	Completed
			I	NCT04173338	Terminated
			II	NCT01639508 NCT05613413	Recruiting
			II	NCT00940225 NCT05200143 NCT03468985 NCT01866410 NCT02795156	Completed
			III	NCT04471428	Active
			I/II	NCT04151563	Withdrawn
			II	NCT04310007 NCT01708954	Active
	Foretinib (11)		II	NCT02034097	Withdrawn
			I/II	NCT01068587	Completed
	Glesatinib (12)		II	NCT02954991	Terminated
	Merestinib (13)		II	NCT02920996	Terminated
	Ningetinib (14)		II	NCT03838848	Terminated
	BMS-777607 (15)		I/II	NCT00605618	Completed
			I	NCT01721148	Completed
III	Tivantinib (16)		III	NCT01377376	Terminated